<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011722</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10297</org_study_id>
    <secondary_id>ABT-CIP-10308</secondary_id>
    <nct_id>NCT04011722</nct_id>
  </id_info>
  <brief_title>Portico NG Approval Study</brief_title>
  <official_title>Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the acute safety and effectiveness of the
      next-generation Portico™ NG Transcatheter Aortic Heart Valve as assessed by the rate of
      all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30
      days in a high or extreme surgical risk patient population to support CE (Conformité
      Européenne) Mark and FDA approval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Portico NG Approval study will be conducted as a prospective, multi-center,
      international, single-arm investigational study.

      Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe
      native aortic stenosis who are determined by an independent subject selection committee to
      meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will
      undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach
      according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement)
      procedure.

      Subjects participating in the clinical study will be followed for a total of 12 months with
      data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up
      at 30 days, 12 months and annually at 2, 3, 4 and 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Devices under investigation in this clinical study include the Portico™ NG Valve (23mm, 25mm, 27mm and 29mm sizes), FlexNav™ Delivery System(s) (small and large) and Portico™ NG Loading System(s) (small and large), all of which are currently approved for investigational use only.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary safety endpoint is all-cause mortality</measure>
    <time_frame>at 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary effectiveness endpoint is moderate or greater paravalvular leak</measure>
    <time_frame>at 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Symptomatic Severe Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Portico™ NG valve, FlexNav™ Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portico™ NG Valve and FlexNav™ Delivery System</intervention_name>
    <description>Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.</description>
    <arm_group_label>Portico™ NG valve, FlexNav™ Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documented
             heart team agreement of high or extreme risk for surgical aortic valve replacement due
             to frailty or co-morbidities not captured by the STS score.

          -  Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart
             Association) Functional Classification of II, III, or IV.

          -  Subject has senile degenerative aortic valve stenosis with echo-derived criteria,
             defined as: aortic valve area (AVA) of ≤ 1.0 cm2 (or indexed EOA (effective orifice
             area) ≤ 0.6 cm2/m2) AND mean gradient ≥40 mmHg or peak jet velocity ≥ 4.0 m/s or
             doppler velocity index (DVI) ≤0.25. (Qualifying AVA baseline measurement must be
             within 90 days prior to informed consent).

          -  Aortic annulus diameter of 19-27mm and ascending aorta diameter of 26-42 mm for the
             specified valve size listed in the IFU (Instructions For Use), as measured by CT
             (Computed Tomography) conducted within 12 months prior to informed consent. (If a CT
             is contraindicated and/or not possible to be obtained for certain subjects, a 3D
             echocardiogram and non-contrast CT of chest and abdomen/pelvis may be accepted).

        Exclusion Criteria:

          -  Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as
             evidenced on 12 Lead ECG) within 30 days prior to index procedure.

          -  Any percutaneous coronary or peripheral interventional procedure performed within 30
             days prior to index procedure.

          -  Blood dyscrasias as defined: leukopenia (WBC&lt;3000 mm3), acute anemia (Hb &lt; 9 g/dL),
             thrombocytopenia (platelet count &lt;50,000 cells/mm³). History of bleeding diathesis or
             coagulopathy

          -  Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that
             would preclude anticoagulation

          -  Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA)
             or a transient ischemic attack (TIA).

          -  Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation 3-4+).

          -  Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic
             ring, severe circumferential mitral annular calcification (MAC) which is continuous
             with calcium in the left ventricular outflow tract (LVOT), severe (greater than or
             equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary
             compromise.

          -  Minimum access vessel diameter of &lt;5.0mm for small FlexNav™ Delivery System and &lt;5.5
             mm for large FlexNav™ Delivery System
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mira Tissari</last_name>
    <phone>+32 470 47 0942</phone>
    <email>mira.tissari@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary-Margaret Seale</last_name>
    <phone>+1 612 513 0822</phone>
    <email>mary.seale@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raj Makkar, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Raj Makkar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Robles Regional Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Fontana, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Fontana, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Waksman, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ron Waksman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravi Ramana, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ravi Ramana, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hermiller, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>James Hermiller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassem Chehab, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Bassem Chehab, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaurav Dhar, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Gaurav Dhar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Sorajja, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Paul Sorajja, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susheel Kodali, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Susheel Kodali, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Health &amp; Hospitals</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Groh, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mark Groh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Garrett, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Edward Garrett, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Reardon, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Reardon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Harrington, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Katherine Harrington, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Andrew's Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Worthley, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Worthley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Walton, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Tony Walton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Yong, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Gerald Yong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Soendergaard, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Lars Soendergaard, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Lombard</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Bedogni, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Bedogni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganesh Manoharan, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ganesh Manoharan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital - ABM University Health Board</name>
      <address>
        <city>Morriston</city>
        <state>Swansea</state>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dave Smith, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Dave Smith, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Heart Valve Disease</keyword>
  <keyword>High surgical risk</keyword>
  <keyword>Portico NG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

